Teijin Receives Additional Approval in Japan for Merzs Xeomin Botulinum Toxin Type A
pressreleasepoint.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pressreleasepoint.com Daily Mail and Mail on Sunday newspapers.
Merz Therapeutics: Teijin Receives Additional Approval in Japan for Merz s Xeomin Botulinum Toxin Type A
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Winhealth Pharma and Merz Collaborate on Hepa-Merz to benefit patients with liver disease in China
HANG ZHOU, China, March 9, 2021 /PRNewswire/ On Feb. 26
th, 2021, Hongkong Winhealth Pharma Group Co., Ltd (hereinafter referred to as Winhealth Pharma ) signed a strategic cooperation agreement with Merz Pharmaceuticals GmbH (hereinafter referred to as Merz ). The strategic cooperation between the two parties marks the obtainment of Winhealth Pharma for the exclusive commercial rights of Hepa-Merz (L-ornithine L-aspartate, an important product under Merz product portfolio) in China.
About L-ornithine L-aspartate and hepatic encephalopathy (HE)
L-ornithine L-aspartate (LOLA) is a stable salt of two amino acids that stimulates ammonia detoxification by increasing urea synthesis in the liver and muscle, thereby reducing the blood ammonia content in the brain which causes hepatic encephalopathy in cirrhotic patients.